Incidence of opportunistic illness before and after initiation of highly active antiretroviral therapy in children

Pediatric Infectious Disease Journal

Volumn 32, Issue 10, 2013, Pages 1089-1095

  Nesheim, Steven R ^a,b   Hardnett, Felicia ^c   Wheeling, John T ^d   Siberry, George K ^e   Paul, Mary E ^f   Emmanuel, Patricia ^g   Bohannon, Beverly ^b   Dominguez, Kenneth ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Epidemiology Branch   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NORTHROP GRUMMAN CORPORATION   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Highly active antiretroviral therapy; HIV infection; Immune reconstitution inflammatory syndrome; Opportunistic infection; Pediatric

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; BELL PALSY; BRAIN DISEASE; CANDIDIASIS; CHILD; COHORT ANALYSIS; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; FEMALE; HERPES SIMPLEX; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOLLUSCUM CONTAGIOSUM; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS LOAD; YOUNG ADULT;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; POISSON DISTRIBUTION; UNITED STATES; YOUNG ADULT;

EID: 84891806432     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829ee893     Document Type: Article

References (30)

1. Müller M, Wandel S, Colebunders R, et al.; IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10: 251-261.
2. Murdoch DM, Venter WD, Van Rie A, et al. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 2007;4: 9.
3. Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated bacillus Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine. 2007;25: 14-18.
4. Dunkley-Thompson J, Pierre RB, Steel-Duncan J, et al. Bacille Calmette- Guerin lymphadenitis and immune reconstitution in HIV-infected children on antiretroviral therapy in Jamaica. West Indian Med J. 2008;57: 302-306.
5. Koppel A, Leonardo-Guerrero J, Rives S, et al. Immune reconstitution inflammatory syndrome due to Mycobacterium bovis Bacillus Calmette- Guerin in infants receiving higly active antiretroviral therapy: a call for universal perinatal rapid HIV testing prior to administration of BCG immunization of neonates. J Trop Pediatr. 2009;56: 280-283.
6. Kroidl A, Huck K, Weinspach S, et al. Immune reconstitution inflammatory syndrome (IRIS) due to Bacille Calmette Guerin (BCG) in an HIV-positive child. Scand J Infect Dis. 2006;38: 716-718.
7. Fernandez RC, Araujo LC. Reduced rate of adverse reactions to the BCG vaccine in children exposed to the vertical transmission of HIV infection and HIV-infected children from an endemic setting in Brazil. Eur J Pediatr. 2009;168: 691-696.
8. Waddell RD, Lishimpi K, von Reyn CF, et al. Bacteremia due to Mycobacterium tuberculosis or M. bovis, Bacille Calmette-Guerin (BCG) among HIV-positive children and adults in Zambia. AIDS. 2001;15: 55-60.
9. Steenhof A, Wood SM, Shah SS, et al. Cutaneous Mycobacterium avium complex infection as manifestation of the immune reconstitution syndrome in a human immunodeficiency virus-infected child. PIDJ. 2007;26: 755-757.
10. Puthanakit T, Oberdorfer P, Ukarapol N, et al. Immune reconstitution inflammatory syndrome from non-tuberculosis Mycobacterial infection after initiation of antiretroviral therapy in children with HIV infection. PIDJ. 2006;25: 645-648.
11. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviralinduced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis. 2007;11: 417-423.
12. Puthanakit T, Oberdorfer P, Akarathum N, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J. 2006;25: 53-58.
13. Wang ME, Castillo ME, Montano SM, et al. Immune reconstitution inflammatory syndrome in human immunodeficiency virus-infected children in Peru. Pediatr Infect Dis J. 2009;28: 900-903.
14. Orikiiriza J, Bakeera-Kitaka S, Musiime V, et al. The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children. AIDS. 2010;24: 2009-2017.
15. Smith K, Kuhn L, Coovadia A, et al. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 2009;23: 1097-1107.
16. Siberry G, Tessema S. Immune reconstitution syndrome precipitated by bacilli Calmette Guerin after initiation of antiretroviral therapy. PIDJ. 2006;25: 648-649.
17. Sharp MJ, Mallon DF. Regional bacillus Calmette-Guerin lymphadenitis after initiating antiretroviral therapy in an infant with human immunodeficiency virus type 1 infection. PIDJ. 1998;17: 660-662.
18. Viani RM. Sarcoidosis and interstitial nephritis in a child with acquired immunodeficiency syndrome: implications of immune reconstitution syndrome with an indinavir-based regimen. Pediatr Infect Dis J. 2002;21: 435-438.
19. Oberdorfer P, Washington CH, Katanyuwong K, et al. Progressive multifocal leukoencephalopathy in HIV-infected children: a case report and literature review. Int J Pediatr. 2009;2009: 1-6.
20. Hatherill S, Flisher A. Delirium in children with HIV/AIDS. J Child Neurol. 2009;24: 879-883.
21. Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, et al. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. J Allergy Clin Immunol. 2004;113: 742-746.
22. Levin M. Short-term and Long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. JAIDS. 2009;50: 182-191.
23. Caldwell MB, Oxtoby MJ, Simonds RJ, et al. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR. 1994;43(RR-12): 1-20.
24. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41(RR-17): 1-19.
25. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;44: 599-604.
26. Siberry G, et al. Factors affecting participation in LEGACY: an observational cohort study of HIV-infected children and youth. Poster presented at: XVIIIth International AIDS Conference; July 18-23, 2010; Vienna, Austria.
27. Centers for Disease Control and Prevention. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48(RR-6): 1-5.
28. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56(RR-4): 1-40.
29. Son M. Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis. 2010;201: 1806-1810.
30. Van Dyke R, Patel K, Siberry GK, et al. Antiretroviral treatment of U.S. children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr. 2011;57: 165-173.